Cantex Licenses Intellectual Property from Harvard University to Develop Repurposed Drug Identified by Wyss Institute to Treat Inflammatory Lung Diseases Including Covid-19
Cantex Licenses Intellectual Property from Harvard University to Develop Repurposed Drug Identified by Wyss Institute to Treat Inflammatory Lung Diseases Including Covid-19

Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company based in Weston, FL, and the Wyss Institute for Biologically Inspired Engineering at Harvard University announced yesterday that Cantex has secured a global license from Harvard University’s Office…